<DOC>
	<DOCNO>NCT01548807</DOCNO>
	<brief_summary>This Phase 1 dose escalation study investigational agent , everolimus , give combination standard radiation therapy , prostate cancer rise PSA follow prostatectomy . A maximum 33 people enrol study University Pennsylvania . The primary objective study determine acute chronic toxicity maximum tolerate dose everolimus concurrent radiation .</brief_summary>
	<brief_title>Phase 1 Trial Mammalian Target Rapamycin ( mTOR ) Inhibitor Everolimus Plus Radiation Therapy ( RT ) Salvage Treatment Biochemical Recurrence Prostate Cancer Patients Following Prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must history prostatectomy ( Open Radical Robotic Assisted ) histopathologic documentation adenocarcinoma prostate Patient must biochemical evidence PSA include one following : ) . biochemical recurrence ( define nadir + 2 rise measure least 2 week apart ) b ) . PSA double time le equal 6 month ; OR c ) . persistently elevate PSA ( PSA post prostatectomy 0.2 ng/mL standard assay great 0.05 ultrasensitive PSA assay ) Patient must candidate salvage radiotherapy prostate bed Age great equal 18 year ECOG performance status less equal 1 Adequate bone marrow function Adequate liver renal function Adequate renal function : serum creatinine 1.5 x ULN Signed informed consent Patient must archival prostate tumor block available analysis correlative Indication lymph node radiation ( i.e . evidence LB node metastasis ) Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) Patients , major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery ( define require general anesthesia ) patient may require major surgery course study Prior treatment investigational drug within precede 4 week Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Patients receive immunization attenuate liver vaccine within one week study entry study period . Close contact receive attenuated liver vaccine avoid treatment everolimus . Examples live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation study : 1. . Symptomatic congestive heart failure New York heart Association Class III IV 2. . unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease 3. . severely impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air 4. . uncontrolled diabetes 5. . active ( acute chronic ) uncontrolled severe infection 6. . liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) . Note : A detailed assessment Hepatitis B/C medical history risk factor must do screening patient . HBV DNA HCV RNA PCR test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection . A known history HIV seropositivity everolimus immunosuppressant property Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Patients active , bleeding diathesis Patients receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity everolimus ( RAD001 ) rapamycins ( sirolimus , temsirolimus ) excipients History noncompliance medical regimen Patients unwilling unable comply protocol Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>